Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Mean platelet volume as a biomarker for early detection of primary open-angle glaucoma

Search Title by author or title

Session Details

Session Title: Glaucoma II

Session Date/Time: Monday 12/09/2016 | 08:00-10:30

Paper Time: 08:12

Venue: Hall C4

First Author: : U.Yadava INDIA

Co Author(s): :    A. Garg   A. Kumar   A. Mutreja   U. Raina   V. Yadav   R. Jain     

Abstract Details

Purpose:

To assess the correlation of Mean Platelet Volume (MPV) with Primary Open Angle Glaucoma (POAG) diagnosis and or progression.

Setting:

Glaucoma Services at a tertiary eye hospital in New Delhi, India

Methods:

In a case-controlled study, 30 subjects (older than 40 years) were taken in each group. Group A had newly diagnosed OAG patients with or without raised intraocular pressure (IOP); group B had healthy controls. Patients with angle closure, previous intraocular surgery, secondary glaucoma, systemic history of stroke or cardiovascular ischemia and those taking antiplatelet drugs were excluded from the study. Blood samples were collected from all subjects and evaluated for MPV within half an hour.

Results:

Both the case and control groups were matched for age and sex. The MPV obtained in group A was 10.01 ± 1.82 femtoliter (normal value 5-11 femtoliter), while the same obtained in control group was 9.07 ± 1.22 femtoliter. MPV was significantly more in study group (P= 0.011 with paired t-test).

Conclusions:

Mean Platelet Volume is a marker for platelet function and correlates with platelet activity. A higher MPV means a greater tendency to clot and a higher risk of thrombosis. Increased MPV may indicate an impedance in ocular blood flow leading to progressive optic neuropathy. This study indicates a direct correlation of MPV with open angle glaucoma and its progression.

Financial Disclosure:

NONE

Back to previous